Our Programs
Sepal Pharma is developing a portfolio of anti-cancer drugs selectively targeting cancer cells through a new mode of action:- Providing high efficiency
- Reducing the devastating side-effects associated with chemotherapies
Sepal Pharma conducted preliminary clinical studies with the first drug-candidate SPL2101. The company has also built a portfolio of additional novel candidates. These candidates are a result of Sepal Pharma's Medicinal Chemistry program, based on cutting edge optimization expertise combined with a rational screening and profiling process, and are currently at the preclinical stage.
